A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial
Wei‐Chen Tai(Chang Gung University), Seng‐Kee Chuah(Chang Gung University), Yuan‐Hung Kuo(Chang Gung University), Tsung‐Hui Hu(National Sun Yat-sen University), Pao‐Yuan Huang(Kaohsiung Chang Gung Memorial Hospital), Chen‐Hsiang Lee(Kaohsiung Chang Gung Memorial Hospital), Chih‐Ming Liang(Kaohsiung Chang Gung Memorial Hospital), Shih‐Cheng Yang(Kaohsiung Chang Gung Memorial Hospital), Ming‐Tsung Lin(Chang Gung University), Keng‐Liang Wu(Chang Gung University), Cheng‐Kun Wu(Kaohsiung Chang Gung Memorial Hospital), Chung‐Mou Kuo(Kaohsiung Chang Gung Memorial Hospital), Chien‐Ning Hsu(Kaohsiung Medical University)
Cited by 94
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Hepatogastroenterology
|Hepatogastroenterology|2012|536
Pre-S Deletion and Complex Mutations of Hepatitis B Virus Related to Advanced Liver Disease in HBeAg-Negative Patients
|Gastroenterology|2007|232
Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|Liver International|2016|221
Clinical characteristics and prognostic factors of splenic abscess: A review of 67 cases in a single medical center of Taiwan
|World Journal of Gastroenterology|2006|217